Select Page

EG 427

Description: EG 427 pioneers pinpoint gene therapy using HSV-1 for durable treatment of chronic diseases, starting with neurogenic bladder. Preclinical success, aiming for 2023 trials.
Country: France
Based in: Paris
Founded: 2019
Funding Stage: Seed
Tags: ['Biotechnology', 'Genetics', 'Therapeutics']

Categories

Details about how we process your information are available in our Privacy Policy.
Menu – Luxembourg